Microbiology and treatment of diabetic foot infections

The Diabetic Foot: Medical and Surgical Management: Third Edition

Volumn , Issue , 2012, Pages 331-346

  Karchmer, Adolf W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amputations; Foot infection; Infected ulcers; Methicillin resistant S. aureus; Multidrug resistant bacteria; Osteomyelitis; Staphylococcus aureus

Indexed keywords

EID: 84906935109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-791-0_18     Document Type: Chapter

References (72)

1. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29:1288-93.
2. Peters EJG, Lavery LA, Armstrong DG. Diabetic lower extremity infection: influence of physical, psychological, and social factors. J Diabetes Complications. 2005;19:107-12.
3. Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers: diagnosis and monitoring by leukocyte scanning with indium and 111 oxyquinoline. JAMA. 1991;266:1246-51.
4. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18:683-93.
5. Karchmer AW, Gibbons GW. Foot infections in diabetes:evaluation and management. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases. 14th ed. Boston: Blackwell Scientific; 1994. p. 1-22.
6. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively. Arch Intern Med. 1999; 159:851-6.
7. Williams DT, Hilton JR, Harding KG. Diagnosing foot infections in diabetes. Clin Infect Dis. 2004; 39:S83-6.
8. Jeandrot A, Richard JL, Combescure C, et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia. 2008;51:347-52.
9. Wagner Jr FW. The diabetic foot and amputation of the foot. In: Mann RA, editor. Surgery of the foot. 5th ed. St. Louis: CV Mosby; 1986. p. 421-55.
10. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885-910.
11. Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA. Validation of the infectious diseases Society of America's diabetic foot infection classifi-cation system. Clin Infect Dis. 2007;44:562-5.
12. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331:854-60.
13. Sapico FL, Canawah HN, Witte JL, Montgomerie JZ, Wagner FW, Bessman AN. Quantitative aerobic and anaerobic bacteriology of infected feet. J Clin Microbiol. 1980;12:413.
14. Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med. 2004;21:705-9.
15. Pellizzer G, Strazzabosco M, Presi S, et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med. 2001;18:822-7.
16. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis. 2004;39:S104-14.
17. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. 1990;150:790-7.
18. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: soft tissue and bone infection. Infect Dis Clin N Am. 1990;4:409-32.
19. Caputo GM, Ulbrecht JS, Cavanagh PR, Juliano PJ. The role of cultures in mild diabetic foot cellulitis. Infect Dis Clin Pract. 2000;9:241-3.
20. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol. 1999;26:267-76.
21. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalized patients with diabetes: culture isolates and risk factors associated with mortality, length of stay, and cost. Diabetologia. 2010;53:914-23.
22. Dang CN, Prasad YDM, Boulton AJM, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003;20:159-61.
23. Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect. 2006;12:186-9.
24. Yates C, May K, Hale T, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabet Care. 2009;32:1907-9.
25. Scher KS, Steele FJ. The septic foot in patients with diabetes. Surgery. 1988;104:661-6.
26. Citron DM, Goldstein EJC, Vreni Merriam C, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45:2819-28.
27. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabet Care. 2006;29:1727-32.
28. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis. 1995;20 Suppl 2:S283-8.
29. Johnson S, Lebahn F, Peterson LP, Gerding DN. Use of an anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. Clin Infect Dis. 1995;20 Suppl 2:S289-90.
30. Kandemir O, Akbay E, Sahin E, Milcan A, Gen R. Risk factors for infection of the diabetic foot with multi-antiboitic resistant microorganisms. J Infect. 2007;54:439-45.
31. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:1-38.
32. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997;24:643-8.
33. National Diabetes Advisory Board. The national longrange plan to combat diabetes. 9th ed. Washington:U.S. Government Printing Office; 1987.
34. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis. 2004;39:S115-22.
35. American Diabetes Association. Consensus development conference on diabetic foot wound care, April 7-8, 1999, Boston, Massachusetts. Diabet Care. 1999;22:1354-60.
36. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File Jr TM. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis. 1996;23:286-91.
37. van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis. 2004;39:S123-8.
38. McIntyre Jr KE, Bailey SA, Malone JM, Goldstone J. Guillotine amputation in the treatment of non-salvageable lower extremity infections. Arch Surg. 1984;119:450-3.
39. Fox HR, Karchmer AW. Management of diabetic foot infections, including the use of home intravenous antibiotic therapy. Clin Podiatr Med Surg. 1996;13:671-82.
40. Lipsky BA, McDonald D, Litka PA. Treatment of infected diabetic foot ulcers: topical MSI-78 vs. oral ofloxacin. Diabetologia. 1997;40 Suppl 1:482.
41. Chantelan E, Tanudjaja T, Altenhofer F, Ersuli Z, Lacigova S, Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes:a controlled trial. Diabet Med. 1996;13:156-9.
42. Jones EW, Edwards R, Finch R, Jaffcoate WJ. A microbiologic study of diabetic foot lesions. Diabet Med. 1984;2:213-5.
43. Lipsky BA, Itani K, Norden C, The Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38:17-24.
44. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481-90.
45. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, The Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-81.
46. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240-5.
47. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683-93.
48. Wilcox MH, Corey RG, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;64 Suppl 4:53-65.
49. Corey RG, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;64 Suppl 4:41-51.
50. Beam Jr TR, Gutierrez I, Powell S, et al. Prospective study of the efficacy and safety of oral and intravenous ciprofloxacin in the treatment of diabetic foot infections. Rev Infect Dis. 1989;11 Suppl 5:S1163.
51. Hughes CE, Johnson CC, Bamberger DM, et al. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Ther. 1987;10(Suppl A):36-49.
52. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med. 1989;86:801-8.
53. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blind, multicentre trial. Lancet. 2005;366:1695-703.
54. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillintazobactam/ amoxicillin-calvulanate. J Antimicrob Chemother. 2007;60:370-6.
55. Vick-Fragoso R, Hernandez-Oliva G, Cruz-Alcazar J, et al. Efficacy and safety of sequential intravenous/ oral moxifloxacin vs. intravenous/oral amoxicillin/ calvulanate for complicated skin and skin structure infections. Infection. 2009;37:407-17.
56. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract. 2008;80:344-51.
57. Lipsky BA. Empirical therapy for daibetic foot infections:are there clinical clues to guide antibiotic selection? Clin Microbiol Infect. 2007;13:351-3.
58. Cooper G, Platt R. Staphylococcus aureus bacteremia in diabetic patients: endocarditis and mortality. Am J Med. 1982;73:658-62.
59. Berendt AR, Peters EJG, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008;24 Suppl 1:S145-61.
60. Kapoor A, Page S, LaValley M, Gale DR, Felson DT. Magnetic resonance imagine for diagnosing foot osteomyelitis: a meta-analysis. Arch Intern Med. 2007;167:125-32.
61. Teh J, Berendt T, Lipsky BA. Investigating suspected bone infection in the diabetic foot. BMJ. 2010;340:415-7.
62. Vartanians VM, Karchmer AW, Giurini JM, Rosenthal DI. Is there a role for imaging in the management of patients with diabetic foot? Skeletal Radiol. 2009;38:633-6.
63. Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of diabetic patients: long-term results, prognostic factors and the role of antimicrobial and surgical therapy. Am J Med. 1987;83:653-60.
64. Game FL, Jeffocate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia. 2008;51:962-7.
65. Senneville E, Lombart A, Beltrand E, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically. Diabet Care. 2008;31:637-42.
66. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother. 2001;48:927-30.
67. Van GH, Siney H, Danan JP, Sachon C, Grimaldi A. Treatment of osteomyelitis in the diabetic foot. Diabet Care. 1996;19:1257-60.
68. Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis. 2006;42:57-62.
69. Berendt AR, Peters EJG, Bakker K, et al. Specific guidelines for treatment of diabetic foot osteomyelitis. Diabetes Metab Res Rev. 2008;24 Suppl 1:S190-1.
70. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318-26.
71. Eneroth M, van Houtum WH. The value of debridement and vacuum-assisted closure (V.A.C.) therapy in daibetic foot ulcers. Diabetes Metab Res Rev. 2008;24 Suppl 1:S76-80.
72. Gibbons GW, Eliopoulos GM. Infections of the diabetic foot. In: Kozak GP, Hoar Jr CS, Rowbotham RL, editors. Management of diabetic foot problems. Philadelphia: W.B. Saunders; 1984. p. 97-102.